A<sc>ltman</sc>, D. G., L<sc>ausen</sc>, B., S<sc>auerbrei</sc>, W., <sc>and</sc> S<sc>chumacher</sc>, M. 1994. Dangers of using “optimal” cutpoints in the evaluation of prognostic factor. <em>Journal of the National Cancer Institute 86,</em> 11, 829–835.
B<sc>lanco</sc>, J. I. M., B<sc>onilla</sc>, J. A. A., H<sc>omma</sc>, S., S<sc>uzuki</sc>, K., F<sc>remont</sc>-S<sc>mith</sc>, P., <sc>and de</sc> L<sc>as</sc> H<sc>eras</sc>, K. V. G. 2021. Antihistamines and azithromycin as a treatment for COVID-19 on primary health care – a retrospective observational study in elderly patients. <em>Pulmonary pharmacology & therapeutics 67</em>, 101989.
F<sc>reedberg</sc>, D. E., C<sc>onigliaro</sc>, J., W<sc>ang</sc>, T. C., T<sc>racey</sc>, K. J., C<sc>allahan</sc>, M. V., A<sc>brams</sc>, J. A., <sc>and</sc> G<sc>roup</sc>, F. R. 2020. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: a propensity score matched retrospective cohort study. <em>Gastroenterology 159,</em> 3, 1129–1131.
G<sc>reiner</sc>, M., P<sc>feiffer</sc>, D., <sc>and</sc> S<sc>mith</sc>, R. D. 2000. Principles and practical application of the receiver-operating characteristic analysis for diagnostic tests. <em>Preventive veterinary medicine 45,</em> 1–2, 23–41.
H<sc>ogan</sc> II, R. B., H<sc>ogan</sc> III, R. B., C<sc>annon</sc>, T., R<sc>appai</sc>, M., S<sc>tuddard</sc>, J., P<sc>aul</sc>, D., AND D<sc>ooley</sc>, T. P. 2020. Dual-histamine receptor blockade with cetirizine-famotidine reduces pulmonary symptoms in COVID-19 patients. <em>Pulmonary pharmacology & therapeutics 63</em>, 101942.
J<sc>anowitz</sc>, T., G<sc>ablenz</sc>, E., P<sc>attinson</sc>, D., W<sc>ang</sc>, T. C., C<sc>onigliaro</sc>, J., T<sc>racey</sc>, K., AND T<sc>uveson</sc>, D. 2020. Famotidine use and quantitative symptom tracking for COVID-19 in nonhospitalised patients: a case series. <em>Gut 69,</em> 9, 1592–1597.
L<sc>iu</sc>, H., Y<sc>ang</sc>, Y., C<sc>hen</sc>, C., W<sc>ang</sc>, L., H<sc>uang</sc>, Q., Z<sc>eng</sc>, J., L<sc>in</sc>, K., Z<sc>eng</sc>, Y., G<sc>uo</sc>, P., Z<sc>hou</sc>, W., <sc>and</sc> L<sc>iu</sc>, J. 2020. Reclassification of tumor size for solitary HBV-related hepatocellular carcinoma by minimum <em>p</em> value method: a large retrospective study. <em>World journal of surgical oncology 18,</em> 1, 1–10.
M<sc>azumdar</sc>, M. <sc>and</sc> G<sc>lassman</sc>, J. R. 2000. Categorizing a prognostic variable: review of methods, code for easy implementation and applications to decision-making about cancer treatments. <em>Statistics in medicine 19,</em> 1, 113–132.
M<sc>irkes</sc>, E. M., C<sc>oats</sc>, T. J., L<sc>evesley</sc>, J., <sc>and</sc> G<sc>orban</sc>, A. N. 2016. Handling missing data in large healthcare dataset: a case study of unknown trauma outcomes. <em>Computers in Biology and Medicine 75</em>, 203–216.
O<sc>gura</sc>, T. <sc>and</sc> S<sc>hiraishi</sc>, C. 2022. Cutoff value for Wilcoxon-Mann-Whitney test by minimum <em>P-</em>value: application to COVID-19 data. <em>International Journal of Statistics and Probability 11,</em> 3, 1–8.
R<sc>eznikov</sc>, L. R., N<sc>orris</sc>, M. H., V<sc>ashisht</sc>, R., B<sc>luhm</sc>, A. P., L<sc>i</sc>, D., L<sc>iao</sc>, Y. S. J., B<sc>rown</sc>, A., B<sc>utte</sc>, A. J., <sc>and</sc> O<sc>strov</sc>, D. A. 2022. Identification of antiviral antihistamines for COVID-19 repurposing. <em>Biochemical and biophysical research communications 538,</em> 1, 173–79.
Ü<sc>nözkan</sc>, H., Y<sc>ilmaz</sc>, M., <sc>and</sc> D<sc>ere</sc>, A. M. 2020. A stochastic approach to number of corona virus cases. <em>Journal of Applied Mathematics, Statistics and Informatics 16,</em> 2, 67–83.
Z<sc>ou</sc>, K. H., O’M<sc>alley</sc>, A. J., <sc>and</sc> M<sc>auri</sc>, L. 2007. Receiver-operating characteristic analysis for evaluating diagnostic tests and predictive models. <em>Circulation 115,</em> 5, 654–657.